COVID-19 Infection in Patients With Chronic Lymphocytic Leukemia Receiving Acalabrutinib in the Phase 3B ASSURE Study

• Carsten U. Niemann,
• Farrukh T. Awan,
• Laura Fogliatto,
• Eugene Nikitin,
• Olga Samoilova,
• Adel Habib,
• Kayhan Foroutanpour,
• Nataliya Kuptsova-Clarkson,
• Stephen Opat

Affiliations

Carsten U. Niemann

1 Department of Hematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark

Farrukh T. Awan

2 Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA

Laura Fogliatto

3 Hospital de Clinicas de Porte Alegre, Porte Alegre, Brazil

Eugene Nikitin

4 S.P. Botkin’s City Hospital, Moscow, Russian Federation

Olga Samoilova

5 Regional Clinical Hospital, Nizhny Novgorod, Russian Federation

Adel Habib

6 AstraZeneca, Gaithersburg, MD, USA

Kayhan Foroutanpour

6 AstraZeneca, Gaithersburg, MD, USA

Nataliya Kuptsova-Clarkson

6 AstraZeneca, Gaithersburg, MD, USA

Stephen Opat

7 Haematology Department, Monash Health, School of Clinical Sciences, Monash University, Melbourne, Australia